The wide-acting effects of Fasting-Mimicking Diets (FMDs) on metabolic, inflammatory and regenerative pathways leading to reduced pathology or risk factors for various diseases in mice and humans, has the potential to be effective against Alzheimer's disease (AD). It is proposed to conduct a randomized clinical trial of twelve monthly cycles of the ProlonADTM diet (by L-Nutra) vs. placebo diet in patients with aMCI or mild AD (MMSE 18-23). The primary endpoint of the study will be the feasibility and safety of the twelve cycles of ProlonADTM.
Inclusion Criteria: * Age 55-80; * Presence of aMCI or initial AD (MMSE 18-23); * Normal organ function (liver and kidney); * BMI not less than 20 kg/m2; * Bioimpedance phase angle (PA) \> 5 °; * Adherence to informed consent Exclusion Criteria: * Age\> 80 years * Diabetes mellitus; * Organ impairment (liver, kidney); * Food allergies to the components of ProlonADTM; * Patients on therapy with vitamin K antagonist anticoagulants; * PA \<5 °; * Patients who live alone or are not adequately supported by the family context; * Other experimental therapies in progress.